Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult ADPKD patients aged 18-70~* combined kidney volume \>1200 ml~* estimated creatinine clearance \>60 ml/min~* absence of implanted ferromagnetic objects~Exclusion Criteria:~* Age \>70~* uncontrolled hyperlipidemia~* Proteinuria \>500 mg/day~* unstable cerebral aneurysm~* active coronary artery disease~* diagnosis of another systemic condition affecting kidney function (ie: diabetes, hepatitis B or C, HIV)~* diagnosis of cancer other than skin cancer~* pregnancy or lactation~* presence of implanted ferromagnetic objects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Rapamycin (Type: EXPERIMENTAL): Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
- Standard of Care-Placebo (Type: PLACEBO_COMPARATOR): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).